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Background: Mitral valve repair for mitral regurgitation (MR) has been performed by the use of a
surgically created double oriﬁce. Percutaneous repair based on this surgical approach has been
developed by the use of a MitraClip device.
Methods: Five patients with 3 to 4+ MR were selected in accordance with the American Heart
Association/American College of Cardiology guidelines between March 2013 and May 2013 and
underwent percutaneous mitral repair with the MitraClip system with 6 months follow up after
the procedure. The primary acute safety endpoint was freedom from major adverse events (MAEs)
at 30 days. The primary efﬁcacy endpoint was acute procedural success deﬁned as clip implant with
the reduction of MR to equal or less than grade II, based on current guidelines.
Results: No transseptal complications were reported (0%). There was no procedural mortality. No
patients experienced MAE at 30 days. No cases of clip detachment or embolization were observed.
Acute procedural success was achieved in all treated patients (100%). There was an improvement in
the severity of MR in all patients as assessed acutely. Acute MR reduction by 3 grades was achieved
in 2 patients and by 2 grades in 3 patients (reduction P2 grades in 100%).
Conclusions: Our initial results with the MitraClip device in a very small number of patients indi-
cate that percutaneous edge-to-edge mitral valve repair is feasible and may be accomplished with
favorable short-term safety and efﬁcacy results.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Severe mitral regurgitation (MR) caused by primary valve
disease or as a consequence of underlying left ventricular
(LV) dilatation substantially contributes to morbidity and
mortality.1–4 Optimal medical management or cardiac resyn-
chronization therapy can improve symptoms and reduce MR
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fail, mitral valve surgery is the standard therapy. Notably, a
large percentage of patients in need of valve reconstruction
or replacement do not undergo surgery because of a high per-
ioperative risk.7,8
Among the therapeutic options for severe MR, medical
therapy is largely palliative, directed at controlling symptoms
and manifestations of heart failure.9 Surgical intervention is
well tolerated in a population judged by surgeons to be at
acceptable risk; a number of registries and retrospective anal-
yses have provided evidence consistent with the superiority of
surgery over medical therapy, of mitral valve repair over
replacement, and, where replacement has been needed, of pres-
ervation of the subvalvular apparatus. However, in patients at
high surgical risk due to multiple comorbidities, the mandate
for surgery is less compelling.10
Moreover, until the EVEREST II trial randomized patients
to medical therapy versus percutaneous mitral valve repair, the
evidence base was remarkably lacking in high-level clinical tri-
als studying the outcomes of any intervention for severe MR,
surgical or percutaneous.11 Unfortunately, the clinician with a
high-risk patient still does not have a solid evidence base with
which to choose between medical therapy and surgery, given
substantial peri- and postoperative morbidity and mortality
in this population.12
In this context, a variety of less invasive percutaneous treat-
ment options for mitral valve repair have been developed; most
of these techniques are still at an early stage of clinical evalu-
ation.13–20
The MitraClip (Abbott Vascular, Santa Clara CA, USA)
was the ﬁrst percutaneous system for MV repair (CE Mark
granted in 2008) and has been used in over 6000 patients since
2003. Recently, the ﬁrst randomized controlled study in the
ﬁeld of percutaneous MV repair, the EVEREST II trial,Figure 1 The Micompared MitraClip with surgical MV repair and demon-
strated the superior safety of the MitraClip repair and similar
improvements in clinical symptoms.21
The performance of the MitraClip transcatheter procedure
has been restricted to selected centers that fulﬁll certain setup
and multidisciplinary training requirements. Our hospital
was the ﬁrst to employ this novel procedure in Egypt. Herein,
we describe our initial experience, focusing on patient selec-
tion, setup requirements and acute clinical outcomes of this
technique in high-surgical-risk patients.
2. Methods
2.1. Study design
It is a single center, prospective, single armed study that in-
cluded the ﬁrst ﬁve patients for whom percutaneous mitral
valve repair was done via mitral valve clip system at (Wadi
El Neel hospital).
2.2. MitraClip system and procedural technique
We explained the procedure in detail as this is the ﬁrst study
using this novel technique in Egypt, so, other interventionists
can get use of it.
 The MitraClip system includes a MitraClip device, a 24-F
Steerable Guide Catheter (SGC), and a Clip Delivery Sys-
tem (CDS). The Clip is pre-assembled to the tip of the dis-
posable delivery catheter. Opening, closing, locking, and
detaching the clip are all controlled by the delivery catheter
handle mechanism, which is ﬁrmly lodged on a metal, ster-
ilized external support placed outside the patient, on the
bottom of a small table above the upper leg Fig. 1.traclip system.
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avoid any discomfort due to Trans-esophageal echocardiog-
raphy (TOE) monitoring. We used both 2D & 3D echocar-
diography for monitoring and assessing the procedural
success.
 Invasive arterial pressure was monitored through the femo-
ral artery. The right femoral vein was cannulated with an 8-
F introducer sheath then exchanged with an 8-F Mullins
sheath (St. Jude Medical, Minnesota, USA) over a 0.32
guide wire, and a transseptal puncture was performed using
a Brockenbrough needle under TEE guidance.
 This is a critical point of the procedure, because the punc-
ture has to be located in the postero-superior part of the
inter-atrial septum in order to obtain enough room in the
left atrium for a safe and optimal orientation of the steer-
able distal part of the CDS.
 Once the left atrium was entered with the 8F sheath, the
upper left pulmonary vein was cannulated using a 260 cm
Amplatz Super stiff guide wire. After administration of
100 IU/kg of unfractionated heparin, the 24-F SGC was
introduced in the left atrium and the dilator was carefully
and slowly retrieved for avoiding vacuum air bubbles.
 The CDS was then advanced in the left atrium, and the dis-
tal steerable part was manipulated in the atrium for obtain-
ing a perpendicular and central position with respect to the
mitral valve leaﬂets coaptation line.
 The correct trajectory of the clip and the perpendicularity of
the two arms with respect to the mitral leaﬂet coaptation
line are checked using three echocardiographic views:
(i) The three-chambers in which the left atrium, left ventri-
cle, and aortic root are visualized.
(ii) The dual chamber view, in which both left atrium and
ventricle are obtained.
(iii) The trans-gastric short axis view to visualize the coapta-
tion line of the mitral leaﬂets.
 Once the system had been aligned, the clip with opened
arms was advanced into the left ventricle and under TEE
guidance the arms grasp the leaﬂets.
 When a double-oriﬁce had been created and the echocardi-
ography conﬁrms the regurgitation reduction is optimal and
stable without any signiﬁcant diastolic gradient across the
MV; grasping of both leaﬂets, there are two options: if
the position is suboptimal, the clip can be reopened and
repositioned; if the result is good and the grasp is stable,
the clip arms are closed, locked, and detached and the
SGC and CDS are withdrawn.
 The guiding catheter was removed, and venous femoral
access was closed using a ‘ﬁgure-of-eight’ superﬁcial stitch.
 Post-procedural pharmacologic management included aspi-
rin 100 mg lifelong and clopidogrel 75 mg for 3 months in
patients without atrial ﬁbrillation. Patients with atrial ﬁbril-
lation were prescribed aspirin 100 mg and vitamin K
antagonists.
2.3. Patient selection
2.3.1. Inclusion criteria
 Patients with moderate-to-severe (3+) or severe (4+) pri-
mary or secondary MR with symptoms (NYHAclassP II), or if asymptomatic, with compromised LV
function (ejection fraction <60% or end-systolic dimension
>45 mm).
 High risk for surgery (logistic EuroSCORE more than
20%).
 Mitral regurgitation will be graded according to the criteria
of the American Society of Echocardiography (ASE) guide-
lines by the use of quantitative (regurgitant volume, regur-
gitant fraction) and qualitative (color Doppler and
pulmonary venous ﬂow) criteria.
 Key anatomic inclusion criteria included a regurgitant jet
origin associated with the A2 to P2 segments of the mitral
valve and, for patients with secondary MR, a coaptation
length of at least 2 mm, a coaptation depth of no more than
11 mm, and for patients with leaﬂet ﬂail, a ﬂail gap
<10 mm and a ﬂail width <15 mm.
2.3.2. Exclusion criteria
 Evidence of an acute myocardial infarction in the 12 weeks
prior to the intended treatment.
 Mitral valve oriﬁce area less than 4.0 cm2.
 Severe mitral annular calciﬁcation.
 Any leaﬂet anatomy which may preclude clip implantation,
proper clip positioning on the leaﬂets, or sufﬁcient reduc-
tion in MR.
 Need for emergency surgery for any reason.
 Hypertrophic cardiomyopathy.
 Echocardiographic evidence of intra-cardiac mass, throm-
bus, or vegetation.
 History of a stroke or documented TIA within the prior
6 months.
 Patients in whom TEE is contraindicated.
2.4. Study endpoints
 The primary acute safety endpoint is freedom from any of
the major adverse events (MAEs) at 30 days, deﬁned as
the composite of death, myocardial infarction, non-elective
cardiac surgery for adverse events, renal failure, transfusion
of more than 2 units of blood, ventilation for more than
48 h, deep wound infection or septicemia.
 The primary efﬁcacy endpoint is acute procedural success
deﬁned as clip implant with a reduction of MR to equal to
or less than grade II, based on current guidelines. Grade III
MR was assigned as recommended by the American Society
of Echocardiography based on a validated integrative
method and the consensus of two expert observers. In case
of disagreement, the opinion of a third observer was obtained
and the ﬁnal decision was made by consensus. As vena con-
tracta width and regurgitant oriﬁce area have not been vali-
dated for a double-oriﬁce valve, these parameters were not
included among methods to appraise the severity of MR.
We proceeded with the procedure after approval from the
local ethics committee at the Wadi El Neel hospital. The pro-
cedural details were explained to all included patients and a
written consent was signed.
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3.1. Patient characteristics
Five patients were treated, including 3 patients (60%) with
primary or combined primary and secondary disease and 2Table 2 In hospital outcome.
In-hospital outcomes Number (%)
Death unrelated to MitraClip device 0 (0)
Mechanical ventilation >48 h 0 (0)
Bleeding requiring transfusion P2 U (procedural) 0 (0)
Transseptal complications 0 (0)
Length of hospital stay, days 3.2 ± 3.9
Discharge home (without home health care) 5 (100)
Table 1 Baseline demographics and clinical features.
Baseline
(n= 5)
Median age (years), median (range) 63 (50–72)
Logistic euro-SCORE, % 21 ± 5
Age >65 years, % 60
Male sex, % 60
Diabetes mellitus, % 40
Hypertension, % 60
Chronic obstructive pulmonary disease, % 40
History of congestive heart failure, % 80
History of coronary artery disease, % 40
Previous coronary artery bypass graft, % 40
Atrial ﬁbrillation, % 20
Ejection fraction, % (mean) 30
New York heart association functional
class III or IV, %
60
Figure 2 Intra-procedural imapatients (21%) with pure secondary MR. Clinical features
are shown in (Table 1). The median age was 63 years (range
50–72 years), and 60% of patients were older than 65 years
of age, the logistic euro-SCORE was 21 ± 5%. Among pa-
tients with secondary MR, there was a history of coronary ar-
tery disease in 40% and previous bypass surgery in 40%.
3.2. Procedure results
We placed one clip in 4 patients (80%) and a second clip was
needed in only one patient (20%). No transseptal complica-
tions were reported (0%). The procedure time for 4 patients
was in the range of 115–160 min, but it reached 180 min in 1
patient. The mean procedure time was 146 min and the mean
ﬂuoroscopy time was 43 min.
In-hospital outcomes are shown in Table 2. There was no
procedural mortality. No patients experienced MAE at
30 days. One patient with a history of transient ischemic attack
had a non-embolic stroke with a neurological deﬁcit lasting
>72 h, which resolved within 30 days. No cases of clip detach-
ment or embolization were observed. There were no other
complications (see Figs. 2 and 3).
Acute procedural success was observed in all treated pa-
tients (100%). There was an improvement in the severity of
MR in all patients as assessed acutely. Acute MR reduction
by 3 grades was achieved in 2 patients and by 2 grades in 3 pa-
tients (reduction P2 grades in 100%). No signiﬁcant iatro-
genic mitral stenosis was detected after the procedure (mean
mitral valve gradient <4 mmHg in all patients). In addition
to the reduction in MR severity, clinical status, as assessed
by NYHA functional class, improved in 4 patients (80%); at
discharge, these patients were in NYHA functional class I.
4. Discussion
Mitral valve repair can be accomplished with a procedure that
involves the percutaneous implantation of a clip (MitraClip)ge of MitraClip deployment.
Figure 3 The mitral valve before and after the MitraClip deployment.
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the origin of the regurgitant jet. This technology was devel-
oped in an attempt to replicate the surgical approach for mitral
valve repair, which involves approximation of the mitral leaf-
lets with a suture to create a double oriﬁce.22
This report describes the initial experience at the ﬁrst Egyp-
tian center that started a program of MR treatment with the
MitraClip system. We intended to evaluate this therapy in
high-surgical-risk patients with grades 3–4 MR .The majority
of our patients presented with pronounced LV dysfunction
or multiple co-morbidities.
Our study has demonstrated that MitraClip therapy is fea-
sible and effective, with procedural success achieved in all pa-
tients (100%). There was no procedural mortality or MAE at
30 days. Successful placement of the MitraClip device was
associated with a reduction in MR severity by P2 grades in
all patients.
In addition to the reduction in MR severity, clinical status,
as assessed by NYHA functional class, improved in 4 patients
(80%) at discharge, these patients were in NYHA functional
class I. Thus, our data show a reduction in MR and corre-
sponding improvement in the clinical status in patients with
limited other therapeutic options. However, it needs to be
studied whether the reduction in MR leads to reversal of ven-
tricular remodeling and ultimately improves prognosis in the
long term.
In comparison with Whitlow et al. who also studied the use
of MitraClip in high risk patients, there was relatively high
procedure-related mortality for a percutaneous approach
(8%). MR graded 2+ or higher was 46% through hospital dis-
charge and 69% at 1 year. Both are high; in EVEREST II, MR
grade of P2+ was 46% at 1 year (17% after surgery). Only
44% had a P2 grade reduction in MR, whereas 19% had
no change or a 1-grade increase. A somewhat more optimisticperspective comes from looking at severe MR only; there was
an 87% reduction to less severe over 12 months, overall left
ventricular dimensions appeared to improve, and New York
Heart Association functional class decreased to I or II in
71% of those who were III or IV at the baseline.23
However, interpretation of these follow-up data can be mis-
leading; the reader needs to take into consideration the impor-
tance of the de facto censoring of 31% of the patients
(including the 24% who died before 1-year follow-up). Thus,
comparisons shown by Whitlow et al. can result in the reader
over interpreting the beneﬁts of MitraClip in this patient
population.
Moreover, the 30-day mortality in the 177 patients with sec-
ondary MR treated with the MitraClip in the EU ACCESS
registry was 2.8%, while in the 149 secondary MR patients
treated with the MitraClip in the EVEREST II high-surgical
risk cohort, it was 4.7% (1.1% in the 50 patients with second-
ary MR randomized to MitraClip in the EVEREST II
trial).24,25
MitraClip is the only percutaneous technology effective for
both functional and degenerative MR. The procedure is per-
formed via a venous route and the device is removable and
repositionable. These important attributes contribute to the
safety of this procedure. Notably, in spite of the fact that the
degree of reduction in MR is lower than that of surgery, the
clinical beneﬁts with respect to LV remodeling were observed
to be similar to the surgical group.
5. Limitations of the study
Although this study represents the ﬁrst experience with
MitraClip therapy reported to date in Egypt, the total number
of 5 patients is still small. A larger number of patients and ade-
quate long-term follow-up is needed to assess the true value of
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gorized by NYHA functional class, which is most widely used
in clinical practice. Measurements such as a 6-min walk test
may provide a more objective perspective, but were not per-
formed at discharge.
6. Conclusion
Our initial results with the MitraClip device in a small number
of patients indicate that percutaneous edge-to-edge mitral
valve repair is feasible and may be accomplished with favor-
able short-term safety and efﬁcacy results. A universal ﬁnding
with the MitraClip therapy, which we also encountered in our
initial experience, is that MR is signiﬁcantly reduced but rarely
eliminated. However, when treating high-risk patients a subop-
timal repair obtained with low risk can be an acceptable
outcome.
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